Akero Therapeutics Reports Third Quarter 2020 Financial Results
Akero Therapeutics (Nasdaq: AKRO) reported its Q3 2020 financial results, highlighting significant advancements in its NASH treatment, efruxifermin (EFX).
The company raised over $216 million through an equity offering and received FDA feedback facilitating an adaptive Phase 2b/3 clinical trial. EFX also gained PRIME designation from EMA, underscoring its potential in the NASH market.
Cash reserves stood at $291.9 million as of September 30, 2020, while operating expenses increased to $21.5 million for Q3 due to higher research and development costs.
- Raised over $216 million in an upsized equity offering to fund EFX development.
- Received FDA feedback allowing for an adaptive Phase 2b/3 clinical trial design.
- Achieved PRIME designation from EMA for EFX, enhancing regulatory support.
- Operating expenses increased to $21.5 million in Q3, up from $16.3 million the previous year.
- Research and development expenses rose to $17.4 million for Q3, compared to $13.9 million in 2019.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today reported third quarter financial results for the period ending September 30, 2020.
"On the heels of reporting strongly positive histological data from our FGF21 analog, efruxifermin (EFX), we executed a number of important objectives in the third quarter that position us for continued success," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "In addition to raising more than
Third Quarter Business Highlights
- On July 10th, the Company closed an upsized underwritten public offering of 6,012,390 shares of common stock at a price of
$36.00 per share. Gross proceeds from the offering, before deducting underwriting discounts, commissions and offering expenses, were approximately$216.4 million . - On July 21st, the Company announced publication of data in the journal Cell Reports Medicine from the Phase 1b clinical trial of EFX, which showed its potential to modulate biomarkers associated with metabolic diseases, including NASH.
- On Sept. 24th, the Company announced that written guidance from the U.S. Food and Drug Administration (FDA) enables implementation of an innovative combined Phase 2b/3 study design for a pivotal EFX clinical trial in NASH patients with F2-F3 fibrosis. Under the planned adaptive trial design, the Company will evaluate the 28 and 50mg EFX doses in a 24-week Phase 2b portion of the trial to inform selection of one of these doses for evaluation in the Phase 3 portion of the study.
- On Sept. 30th, the Company announced enrollment had been completed for a cohort of the BALANCED study (Cohort C), which is investigating the effects of 16 weeks of EFX treatment on patients with NASH who have compensated cirrhosis (F4), Child-Pugh Class A. The Company expects results from this study cohort to inform long-term development plans for EFX to treat cirrhotic NASH patients, who are at greatest risk of progressing to end-stage liver disease. The Company expects to report the results of the F4 expansion cohort in the first half of 2021.
- On Oct. 16th, the Company announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to EFX for treatment of NASH. The designation was based on the positive efficacy data reported from the Company's Phase 2a BALANCED study. The PRIME program is designed to enhance regulatory support in the EU for the development of promising investigational medicines that target unmet medical need.
Manufacturing Update
- Manufacture of GMP drug substance (API) at commercial scale was completed in April 2020. GMP drug product for the Company's anticipated Phase 2b clinical trial was manufactured from this API in September 2020.
- A new lyophilized formulation is being developed for commercial drug product. This formulation will be used for the Phase 3 portion of the adaptive clinical trial design. Scale-up of manufacturing for this new drug product formulation began during the third quarter of 2020 and is expected to be completed in 2022.
Regulatory Update
- Submission of multiple Investigational New Drug (IND) amendments are ongoing to support the Phase 2b portion of the adaptive Ph2b/3 study design. The Company remains on track to initiate Phase 2b in the first half of 2021.
Financial Highlights
- Akero's cash, cash equivalents and short-term marketable securities at September 30, 2020 were
$291.9 million , which includes the net proceeds from the July 10th equity offering. - Research and development expenses for the three-month and nine-month periods ended September 30, 2020 were
$17.4 million and$39.2 million , respectively, compared to$13.9 million and$23.9 million for the comparable periods in 2019. These increases are attributable to higher costs related to Akero's EFX program, including third-party contract manufacturing and contract research organization costs associated with the BALANCED study and internal personnel costs, including non-cash stock-based compensation. - General and administrative expenses for the three-month and nine-month periods ended September 30, 2020 were
$4.2 million and$11.2 million , respectively, compared to$2.4 million and$5.5 million for the comparable periods in 2019. These increases are attributable to higher internal personnel costs, including non-cash stock-based compensation and professional services and other costs associated with operating as a public company. - Total operating expenses for the three-month and nine-month periods ended September 30, 2020, were
$21.5 million and$50.4 million , respectively, compared to$16.3 million and$29.4 million for the comparable periods in 2019.
About NASH
NASH (non-alcoholic steatohepatitis) is a serious form of NAFLD (non-alcoholic fatty liver disease) and is estimated to affect 17 million Americans. NASH is closely linked to the obesity and diabetes epidemics seen around the world. NASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. As a result, NASH has become a leading cause of liver transplants in the US and Europe.
About Efruxifermin
Efruxifermin (EFX), formerly AKR-001, is Akero's lead product candidate for NASH. EFX has been shown to increase insulin sensitivity, improve lipoproteins, reduce liver fat and inflammation, and reverse fibrosis. The breadth of desirable metabolic effects offers potential to address the complex, multi-organ/tissue pathogenesis of NASH, including risk factors linked to cardiovascular disease – the leading cause of death in NASH patients. Engineered to mimic the biological activity profile of native human FGF21, EFX offers convenient once-weekly dosing.
About Akero Therapeutics
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, efruxifermin, has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study. Akero Therapeutics is headquartered in South San Francisco, CA. For more information, please visit www.akerotx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding the Company's business plans and objectives, including future plans or expectations for EFX, upcoming milestones, and therapeutic effects of EFX, as well as the dosing, safety and tolerability of EFX; the potential benefits resulting from the PRIME designation of EFX; Akero's Phase 2a BALANCED study and Phase 2b/3 study including results and expected timing to complete Cohort C; expectations regarding the design, implementation, timing, and success of its current and planned clinical trials for EFX; expectations regarding successful scale-up of drug substance manufacturing and release of new drug product for use in clinical trials, including new product formulations; expectations regarding the Company's use of capital, expenses and other future financial results; statements regarding the timing of Company's efforts regarding the IND amendments; the Company's planned efforts to prepare for commercialization of EFX, if approved and the potential impact of COVID-19 on strategy, future operations, enrollment and clinical trials. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the impact of COVID-19 on the Company's ongoing and future operations, including potential negative impacts on Akero's employees, third-parties, manufacturers, supply chain and production as well as on global economies and financial markets; the success, cost, and timing of the Company's product candidate development activities and planned clinical trials; the Company's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; the Company's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in Akero's Annual Report on Form 10-K for the year ended December 31, 2019 and most recently filed Quarterly Report on 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero's other filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Akero Therapeutics, Inc. | ||||||
Condensed Consolidated Balance Sheets | ||||||
(Unaudited) | ||||||
(In thousands) | ||||||
September 30, 2020 | December 31, 2019 | |||||
Assets | ||||||
Cash and cash equivalents and short-term marketable securities | $ | 291,870 | $ | 136,400 | ||
Other current assets | 6,163 | 1,649 | ||||
Non-current assets | 2,003 | 69 | ||||
Total assets | $ | 300,036 | $ | 138,118 | ||
Liabilities and Stockholders' Equity | ||||||
Current liabilities | $ | 12,014 | $ | 9,369 | ||
Non-current liabilities | 1,564 | 23 | ||||
Stockholders' equity | 286,458 | 128,726 | ||||
Total liabilities and stockholders' equity | $ | 300,036 | $ | 138,118 | ||
Akero Therapeutics, Inc. | ||||||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||
(Unaudited) | ||||||||||||
(In thousands, except share and per share amounts) | ||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 17,379 | $ | 13,885 | $ | 39,207 | $ | 23,908 | ||||
General and administrative | 4,159 | 2,424 | 11,164 | 5,522 | ||||||||
Total operating expenses | 21,538 | 16,309 | 50,371 | 29,430 | ||||||||
Loss from operations | (21,538) | (16,309) | (50,371) | (29,430) | ||||||||
Other income | 135 | 755 | 875 | 1,286 | ||||||||
Net loss | $ | (21,403) | $ | (15,554) | $ | (49,496) | $ | (28,144) | ||||
Comprehensive loss | $ | (21,477) | $ | (15,554) | $ | (49,474) | $ | (28,144) | ||||
Net loss per common share, basic and diluted | $ | (0.63) | $ | (0.56) | $ | (1.63) | $ | (2.66) | ||||
Weighted-average number of shares used in | 34,002,769 | 28,024,779 | 30,381,671 | 10,589,119 | ||||||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-reports-third-quarter-2020-financial-results-301172303.html
SOURCE Akero Therapeutics, Inc.
FAQ
What were Akero Therapeutics' Q3 2020 earnings results?
What significant milestones did Akero achieve in Q3 2020?
What are the implications of the PRIME designation for Akero's EFX?
When does Akero plan to initiate its Phase 2b clinical trial?
